- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03429608
Quantitative Estimation of Thrombus Burden in Patients With STEMI Using Micro-Computed Tomography (QUEST-STEMI) (QUEST-STEMI)
Quantitative Estimation of Thrombus Burden in Patients With ST Elevation Acute Myocardial Infarction (STEMI) With the Use of Micro-computed Tomography-A Methodological Approach (QUEST-STEMI)
The study aims to assess for the first time, through the application of innovative technologies (micro-CT), important characteristics of aspirated thrombi (such as their volume and their density), which might be linked to certain clinical outcomes, in patients presenting with STEMI and referred for primary Percutaneous Coronary Intervention (PCI). To this end, a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi will be developed. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume and their density will be calculated with the use of micro-CT. Having a better resolution than conventional computed tomography, micro-CT will allow us to create 3D models of aspirated thrombi from a series of x-ray projection images. These 3D models will be further analyzed in order to find the volume and the density of aspirated thrombi. Shape analysis of the surface of aspirated thrombi and potential differences in their structure will also be assessed. Correlation of these variables with clinical parameters and angiographic outcomes will be attempted.
Thus, a risk-stratification model will be developed combining:
- Clinical and laboratory data,
- Angiographic parameters,
- Data regarding the volume, the density and the composition of aspirated thrombi.
This model will enable the stratification of the cardiovascular and cerebrovascular risk of patients and the identification of who will benefit from thrombus aspiration, providing a personalized approach in treating patients with STEMI.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Acute myocardial infarction with ST elevation (STEMI) remains one of the leading causes of mortality in developed countries, in spite of the important advances in pharmacological therapy and in mechanical reperfusion therapy. Having an important role in provoking ischemia, thrombus has been studied in many clinical trials and high thrombus burden has been proven to be an independent risk factor for stent thrombosis and for Major Adverse Clinical outcomes. However large randomized controlled trials concerning thrombus aspiration showed controversial results, providing as a whole no evidence of distinct benefits for thrombus aspiration. A possible explanation could be that aspiration was performed as a routine strategy in all of these trials, whereas these patients should be considered as a heterogeneous group and thus they should be risk-stratified. For this reason, it is of paramount importance to classify patients according to the volume of thrombus burden. The currently existing classifications of thrombus burden (the most important being those of Gibson and of Sianos) are based on visual assessment of angiographic characteristics and thus they are not reflecting the volume of the thrombi in actual, absolute numbers.
The main purpose of the study is to develop a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi in patients presenting with STEMI and referred for primary PCI. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume will be calculated with the use of micro-CT. The scanning procedure results into a series of projection images arranged in the form of image stacks which, in turn, are reformed in sections (cross section images) with the use of the NRecon (Bruker, Kontich, Belgium) software, which applies a modified algorithm of backward projection Feldkamp. The resulting sections will be combined to create the 3D models which will be further analyzed to extract useful measurements for the characteristics of the thrombi, such as for the volume and the elative density. Shape analysis on the surface and internal structure of the three-dimensional representations of the specimens will lead to the identification of the important features that can be used to estimate variability within samples and perform clustering for the significant differences between clots. In addition, possible differences in clot internal and external structure (e.g. architecture of the various cell types) will be assessed through the 3D models rendered from the stacks of images The Secondary end points of the study include the examination of the association of the aforementioned variables with the angiographic classification of thrombus burden (according to Sianos), with electrocardiographic and angiographic characteristics suggestive of poor patient prognosis and with major adverse cardiac events during the follow-up period of one year.
This method could become the gold standard for the exact measurement of thrombus burden and could be used in larger, clinically-oriented trials to help stratify patients with thrombus burden according to their risk for adverse outcomes.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Thessaloníki, Grecia, 54636
- University General Hospital of Thessaloniki AHEPA
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Patients presenting with symptoms of myocardial ischemia lasting for more than 30 minutes
- Definite ECG changes indicating STEMI
- Patients undergoing primary PCI within 12 hours from symptom onset
- Possibility to perform thrombus aspiration
- Age>18 years
- Written informed consent prior to enrolment in the clinical trial
Exclusion Criteria:
- Treatment with fibrinolytic therapy for qualifying index STEMI event
- Patients with known intolerance to aspirin, ticagrelor or heparin
- Patients with active internal bleeding
- Patients with a recent history of intracranial hemorrhage
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Solo caso
- Perspectivas temporales: Futuro
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
pacientes con baja carga de trombo
pacientes con el volumen más bajo de trombos aspirados, medido usando micro-CT
|
|
pacientes con alta carga de trombo
pacientes con el mayor volumen de trombos aspirados, según lo medido usando micro-CT
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
volume of aspirated thrombus burden
Periodo de tiempo: 12 months
|
The volume of aspirated thrombi will be quantified using micro-CT.
|
12 months
|
|
density of aspirated thrombus burden
Periodo de tiempo: 12 months
|
The density of aspirated thrombi will be quantified using micro-CT.
|
12 months
|
|
MACCE-free survival
Periodo de tiempo: 12 months
|
Time between the date of diagnosis and MACCE during the follow-up period of 12 months.
MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
|
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
association between thrombus volume with factors from patients medical history
Periodo de tiempo: 12 months
|
Potential association of thrombus volume (as assessed using micro-ct) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
|
12 months
|
|
association between thrombus density with factors from patients medical history
Periodo de tiempo: 12 months
|
Potential association of thrombus density ( as assessed using micro-CT) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
|
12 months
|
|
Correlation of the volume of aspirated thrombus burden with the Sianos' classification of thrombus burden
Periodo de tiempo: 12 months
|
Potential correlation of the volume of aspirated thrombus burden, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored.
According to Sianos' classification thrombi are classified in the following categories: G0,G1,G2,G3,G4.
|
12 months
|
|
Correlation of thrombus density with the Sianos' classification of thrombus burden
Periodo de tiempo: 12 months
|
Potential correlation of thrombus density, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored.
|
12 months
|
|
association of thrombus volume with electrocardiographic outcomes suggestive of poor patient prognosis
Periodo de tiempo: 12 months
|
Potential association of thrombus volume as measured using micro-CT with ST segment resolution will be explored.
ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
|
12 months
|
|
association of thrombus density with electrocardiographic outcomes suggestive of poor patient prognosis
Periodo de tiempo: 12 months
|
Potential association of thrombus density as measured using micro-CT with ST segment resolution will be explored.
ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
|
12 months
|
|
association of thrombus volume with post-procedural Thrombolysis in Myocardial Infarction(TIMI) flow
Periodo de tiempo: 12 months
|
Potential association of thrombus volume as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
|
12 months
|
|
association of thrombus density with post-procedural TIMI flow
Periodo de tiempo: 12 months
|
Potential association of thrombus density as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
|
12 months
|
|
association of thrombus volume with myocardial blush grade
Periodo de tiempo: 12 months
|
Potential association of thrombus volume as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
|
12 months
|
|
association of thrombus density with myocardial blush grade
Periodo de tiempo: 12 months
|
Potential association of thrombus density as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
|
12 months
|
|
association of thrombus volume with distal embolization .
Periodo de tiempo: 12 months
|
Potential association of thrombus volume as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
|
12 months
|
|
association of thrombus density with distal embolization .
Periodo de tiempo: 12 months
|
Potential association of thrombus density as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
|
12 months
|
|
association of thrombus volume with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Periodo de tiempo: 12 months
|
Potential association of thrombus volume, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored.
MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
|
12 months
|
|
association of thrombus density with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Periodo de tiempo: 12 months
|
Potential association of thrombus density, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored.
MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Georgios Sianos, MD,PhD, FESC, Associate Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
- Investigador principal: Efstratios Karagiannidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
- Investigador principal: Charalambos Karvounis, MD,Phd, Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
- Investigador principal: George Giannakoulas, MD,Phd, Assistant Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
- Investigador principal: Christos Arvanitidis, Phd, Director of Research, Hellenic Center for Marine Research
- Investigador principal: Ioannis Vizirianakis, PharmD, PhD, Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki
- Investigador principal: James S Michaelson, MD,Phd, Associate Professor, Department of Pathology, Harvard Medical School
- Investigador principal: Kleoniki Keklikoglou, MSc, HELLENIC CENTER FOR MARINE RESEARCH
- Investigador principal: Ivelin Samra, MD, Head of cardiology department at MHAT"Hadzy Dimityr" Sliven
- Investigador principal: Nikolaos Konstantinidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
- Investigador principal: Georgios Sofidis, MD,Phd, Aristotle University Of Thessaloniki
Publicaciones y enlaces útiles
Publicaciones Generales
- Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. doi: 10.1016/j.jacc.2007.04.059. Epub 2007 Jul 30.
- Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010 Oct;22(10 Suppl B):6B-14B.
- Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E; TIMI Study Group. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29;103(21):2550-4. doi: 10.1161/01.cir.103.21.2550.
- Elgendy IY, Huo T, Bhatt DL, Bavry AA. Is Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention? Meta-Analysis of Randomized Trials. Circ Cardiovasc Interv. 2015 Jul;8(7):e002258. doi: 10.1161/CIRCINTERVENTIONS.114.002258.
- Karagiannidis E, Papazoglou AS, Sofidis G, Chatzinikolaou E, Keklikoglou K, Panteris E, Kartas A, Stalikas N, Zegkos T, Girtovitis F, Moysidis DV, Stefanopoulos L, Koupidis K, Hadjimiltiades S, Giannakoulas G, Arvanitidis C, Michaelson JS, Karvounis H, Sianos G. Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. Front Cardiovasc Med. 2021 Apr 21;8:646064. doi: 10.3389/fcvm.2021.646064. eCollection 2021.
- Karagiannidis E, Konstantinidis NV, Sofidis G, Chatzinikolaou E, Sianos G. Rationale and design of a prospective, observational study for the QUantitative EStimation of Thrombus burden in patients with ST-Elevation Myocardial Infarction using micro-computed tomography: the QUEST-STEMI trial. BMC Cardiovasc Disord. 2020 Mar 11;20(1):125. doi: 10.1186/s12872-020-01393-5.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 20170210
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .